The 3rd TB Meeting ” Inhaled Therapies for Tuberculosis and other Infectious Diseases” focuses on tuberculosis and intends from TB therapy to translate products, technologies and procedures for efficiently treatingpulmonary infective diseases. The meeting will be in Parma, 14-16 October 2015 (see the programme). Aerosol therapy for the treatment of tuberculosis and pulmonary infections is growing due to the accessibility of local targeting, the complexities of treatment by conventional routes and the impressive advancement of inhalation technology. The understanding of the molecular and cellular mechanisms, local immunology and pathophysiology of tuberculosis dictates the strategies for delivering selected drugs and vaccines to the site of infection for successful outcomes in this important therapeutic endeavor. Difficulties may be experienced with respect to delivery of two or three potent but poorly bioavailable drugs, barriers to the treatment due to co-infection, impact of pathophysiology factors on the fate of inhaled medicines or multidrug resistance. Due to the long duration of therapy and drug combination required, treating TB by inhalation could teach how to translate the therapy outcomes to other infections prevalent in cystic fibrosis, bronchiectasis or COPD.
